Received Apr 15, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| VARZOS | ZOSTER (SHINGRIX) | GLAXOSMITHKLINE BIOLOGICALS | 2 | — | — |
Late 2nd dose; This non-serious case was reported by a pharmacist via call center representative and described the occurrence of drug dose administration interval too long in a patient who received Herpes zoster (Shingrix) for prophylaxis. Previously administered products included Shingrix (Patient received first dose over a year ago). On 08-APR-2025, the patient received the 2nd dose of Shingrix. On an unknown date, an unknown time after receiving Shingrix, the patient experienced drug dose administration interval too long (Verbatim: Late 2nd dose). The outcome of the drug dose administration interval too long was not applicable. Additional Information: GSK Receipt Date: 08-APR-2025 Reporter stated that a patient missed their second Shingrix dose. Patient went on the day of reporting for a Shingrix vaccine and saw they were over a year overdue. The patient received 2nd dose of Shingrix, later than the recommended interval, which led to lengthening of vaccinations schedule.